Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Non-Current Assets (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Non-Current Assets for 4 consecutive years, with $9.2 million as the latest value for Q3 2025.

  • Quarterly Non-Current Assets rose 209.1% to $9.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Sep 2025, up 209.1% year-over-year, with the annual reading at $9.2 million for FY2025, 209.1% up from the prior year.
  • Non-Current Assets hit $9.2 million in Q3 2025 for Jin Medical International, up from $3.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $9.2 million in Q3 2025 to a low of $1.8 million in Q3 2023.
  • Historically, Non-Current Assets has averaged $4.0 million across 4 years, with a median of $2.5 million in 2022.
  • Biggest five-year swings in Non-Current Assets: decreased 12.22% in 2023 and later soared 209.1% in 2025.
  • Year by year, Non-Current Assets stood at $2.0 million in 2022, then decreased by 12.22% to $1.8 million in 2023, then skyrocketed by 66.96% to $3.0 million in 2024, then skyrocketed by 209.1% to $9.2 million in 2025.
  • Business Quant data shows Non-Current Assets for ZJYL at $9.2 million in Q3 2025, $3.0 million in Q3 2024, and $1.8 million in Q3 2023.